Investigating Novel Immunotherapy Targets in Metastatic RCC
Researchers are exploring new immunotherapy targets, including GPR65, HPK1, ENPP3, and CD70, to treat metastatic renal cell carcinoma. These targets aim to overcome treatment resistance in patients who do not respond to standard immunotherapy regimens.
Why it matters
Advancements in targeted cancer therapies are essential for improving survival rates in patients with treatment-resistant metastatic disease.
In an interview at the 2026 ESMO Congress, Rahul Winayak, MD, postdoctoral fellow at City of Hope, discusses emerging therapeutic targets in metastatic renal cell carcinoma (mRCC) and the need for new treatment strategies for patients whose disease progresses following immunotherapy-containing regimens.
A poster Winayak and colleagues presented at the Congress examined 4 targets being investigated through early-phase therapeutic approaches: GPR65, HPK1, ENPP3, and CD70. These targets represent distinct mechanisms for addressing tumor growth and immune evasion in RCC.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in